Plus   Neg

IPO Lockup Expiration Alert: Applied Molecular Transport Inc. (AMTI)

appliedmoleculartransport 1101 lt

The lockup period of Applied Molecular Transport Inc. (AMTI) ends tomorrow (Dec 2).

Applied Molecular Transport is a clinical-stage biopharmaceutical company developing novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases.

The company has two drug candidates in its pipeline - oral AMT-101 and oral AMT-126.

AMT-101 is under the following ongoing and proposed trials.

-- A phase II monotherapy trial of oral AMT-101 in patients with moderate to severe ulcerative colitis, dubbed LOMBARD, is underway.

-- A phase II trial of oral AMT-101 in combination with anti-TNFa in biologic-naïve, moderate to severe ulcerative colitis patients, dubbed MARKET, is expected to be initiated by this year-end.

-- A phase II clinical trial of oral AMT-101 for the treatment of pouchitis, known as FILLMORE, is slated to be initiated by year-end.

-- A phase II clinical trial of oral AMT-101 in combination with anti-TNFa for the treatment of rheumatoid arthritis, dubbed CASTRO, is expected to be initiated in the first half of 2021.

The top-line data readouts from the above-mentioned four AMT-101 phase II trials are expected beginning in the second half of next year and first half of 2022.


- AMT-126 is currently in preclinical development and filing an IND or CTA to treat serious diseases associated with intestinal epithelial (IE) barrier defects is expected by year-end.

The company made its debut on The Nasdaq Global Select Market on June 5, 2020, offering its shares at a price of $14 per share.

As mentioned above, the 180 day lockup period will end on December 2, 2020.

AMTI opened the first day of trading on June 5 at $25.51 and closed at $17.98 that day. The stock has thus far hit a low of $17.05 and a high of $36.21.

AMTI closed Monday's trading at $31.03, down 5.88%.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT